Carlos Campoy

Insider

First SEC filing: June 30, 2023 · Latest: June 30, 2023

On this page

Insider at

0 buys (P) 0 sells (S) Net: $0 + 5 non-open-market transactions below last 12 months, based on the transactions shown below

Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted

5 other filings hidden

Date	Ticker	Code	Shares	Price	Value	Owned after	Δ own	A/D	vs now
Jan. 12, 2026	ZYME	A	7,700	—	—	7,700 Direct	—	Acquired	(price as of 2026-08-20)
Jan. 12, 2026	ZYME	A	11,500	—	—	11,500 Direct	—	Acquired	(price as of 2026-08-20)
Dec. 10, 2024	ZYME	A	31,000	—	—	31,000 Direct	—	Acquired	(price as of 2026-08-20)
Dec. 7, 2023	ZYME	A	37,000	—	—	37,000 Direct	—	Acquired	(price as of 2026-08-20)
June 30, 2023	ZYME	A	50,000	—	—	50,000 Direct	—	Acquired	(price as of 2026-08-20)
March 16, 2023	CTMX	S	1,748	$1.98	$3,461	38,224 Direct	-4.37%	Disposed	76.8% (price as of 2026-08-20)

P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding

Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.

Options, RSUs and convertible securities reported on Form 4 Table II.

Date	Ticker	Security	Underlying	Exercise price	Expiration	Shares	A/D
Jan. 12, 2026	ZYME	Restricted Stock Unit	Common Stock (7,700)	—	Jan. 12, 2027	7,700	Acquired
Jan. 12, 2026	ZYME	Stock Option (Right to Buy)	Common Stock (11,500)	$23.16	Jan. 11, 2036	11,500	Acquired
Dec. 10, 2024	ZYME	Stock Option (Right to Buy)	Common Stock (31,000)	$13.06	Dec. 9, 2034	31,000	Acquired
Dec. 7, 2023	ZYME	Stock Option (Right to Buy)	Common Stock (37,000)	$9.55	Dec. 6, 2033	37,000	Acquired
June 30, 2023	ZYME	Stock Option (Right to Buy)	Common Stock (50,000)	$8.64	June 29, 2033	50,000	Acquired

Exercise/conversion price is blank when not applicable (e.g. RSUs).

Securities held when first becoming an insider, per SEC Form 3.

Date	Ticker	Security	Shares	Ownership
June 30, 2023	ZYME	No securities are beneficially owned	0	Direct
June 30, 2023	ZYME	No securities are beneficially owned→ Not applicable (0)	0	Direct

Matched by name from proxy statements (DEF 14A) — verify against the filing.

CFO

Fiscal year	Salary	Bonus	Stock awards	Option awards	Non-equity incentive	Pension change	Other	Total
2021	$477,555	—	$160,200	$557,652	$195,797	—	$5,000	$1,396,204
2020	$360,052	—	—	$972,860	$144,723	—	$264,004	$1,741,639

Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.